HRMY
Strong BuyFull HouseAI neutralHarmony Biosciences Holdings, Inc. · Healthcare · United States · $2.4B cap · $38.9M/day traded
$37.54 -1.1% · close 19 Oct · scored 20 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
As of 20 Oct 2026, MoatMap's StockRank for Harmony Biosciences Holdings, Inc. (HRMY) is 100/100, ranked against 24,000+ stocks in 35 markets (Quality 81, Value 73, Momentum 84, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Harmony Biosciences maintains strong profitability and cash conversion powered by its commercial sleep-disorder drug Wakix (pitolisant), with forward-EPS consensus expectations revising upward by 4.8%. However, the unexpected planned departure of its chief executive introduces near-term governance and strategic execution uncertainty at a crucial moment when the company must diversify its pipeline beyond a single commercial asset and manage long-term exclusivity challenges.
ABOUT HARMONY BIOSCIENCES HOLDINGS, INC.
Read
Harmony Biosciences Holdings, Inc. is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients suffering from rare neurological diseases. With its flagship product WAKIX for narcolepsy already commercialized, the company establishes a strong market position by addressing significant unmet medical needs within niche neurological disorder markets.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 437.9M | 582.0M | 714.7M | 868.5M | 25.6% | 959.9M | 1.0B | 1.2B | 15.9% |
| EPS | 3.07 | 2.17 | 2.56 | 2.76 | -3.5% | 3.10 | 4.00 | 5.13 | 36.3% |
| Shares | 59.6M | 56.8M | 57.1M | 57.7M | -3.2% | 58.2M | — | — | — |
| Debt | 191.6M | 193.6M | 179.3M | 163.7M | -5.1% | 160.2M | — | — | — |
| Equity | 402.8M | 467.0M | 659.2M | 870.2M | 29.3% | — | — | — | — |
| Op CF | 144.5M | 219.4M | 219.8M | 348.2M | 34.1% | 355.1M | — | — | — |
| Inv CF | -141.8M | -46.4M | -67.5M | -39.6M | — | — | — | — | — |
| Fin CF | 6.8M | -105.6M | -11.0M | -9.0M | — | — | — | — | — |
Above its 200-day average and 14% below its 52-week high.
Swung more than 50% of stocks we rank over the past year (41% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HRMY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HRMY | Harmony Biosciences Holdings, Inc.(you) | $2.4B | 100 | Strong Buy |
| NRIX | Nurix Therapeutics, Inc. | $2.5B | 95 | Strong Buy |
| INVA | Innoviva, Inc. | $1.5B | 93 | Strong Buy |
| RIGL | Rigel Pharmaceuticals, Inc. | $899M | 98 | Strong Buy |
| ADMA | ADMA Biologics, Inc. | $2.2B | 80 | Buy |
| CRMD | CorMedix Inc. | $599M | 98 | Strong Buy |
| ACAD | ACADIA Pharmaceuticals Inc. | $4.4B | 80 | Strong Buy |
| PBYI | Puma Biotechnology, Inc. | $479M | 98 | Strong Buy |
| ZVRA | Zevra Therapeutics, Inc. | $672M | 91 | Strong Buy |
| ABUS | Arbutus Biopharma Corporation | $961M | 81 | Strong Buy |
Peer medians: ROE -26.0% · P/E 29.2x · Gross margin 63.6%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.